Figure 1 Our quality journey Quality improvement and practice-based research in neurology using the electronic medical record (EMR) consists of a stepwise.

Slides:

Advertisements

Similar presentations

Butte Lab Journal Club 16 Aug 2010 Alexander A. Morgan.

Advertisements

My Own Health Report: Case Study for Pragmatic Research Marcia Ory Texas A&M Health Science Center Presentation at: CPRRN Annual Grantee Meeting October.

CMS Physician Quality Reporting J. Marc Overhage, MD, PhD Director of Medical Informatics, Regenstrief Institute Regenstrief Professor of Medical Informatics,

HS420 Health Informatics Michele Smith, PharmD, RPh, RCph Unit Seven Data Quality Tools.

The Holistic Approach to the Design and Meaningful Use of Electronic Health Records: A Nursing Experience Frances Beadle, MSc Health Informatics Nurse.

1 The Holistic Approach to the Design and Meaningful Use of Electronic Health Records: A Nursing Experience Frances Beadle, MSc Health Informatics Nurse.

HS420 Health Informatics Michele Smith, PharmD, RPh, RCph

Figure Pedigrees of the SCA42 families identified in this study

Figure Flow of funds for a 340B agreement for fingolimod

Figure 1 Percentages of patients with first seizure experiencing a recurrent seizure over time This graph is based on a fixed-effect pooled percentage.

Introduction to Electronic Health Records

Figure 2. Change in total PSPRS score from baseline to each study visit for all participants Change in total PSPRS score from baseline to each study visit.

Figure Brain MRI of the patient throughout the disease course(A) Brain MRI at the time of cerebral toxoplasmosis diagnosis (a) and after 1 month of toxoplasmosis.

Figure 2 FXTAS Rating Scale scores for case 1

Figure Revised Niemann-Pick disease type C (NP-C) diagnostic algorithm for the use of biomarkers and genetic testing Revised Niemann-Pick disease type.

Figure 1 Flow diagram of the assays and the samples that were evaluatedA total of 1,109 samples were initially screened at a serum dilution of 1:20 for.

Figure 2 Primary and secondary outcomes reported in multiple sclerosis (MS) disease-modifying therapy (DMT) clinical trials Primary and secondary outcomes.

Figure 1 Outcomes of greatest importance to selection of a multiple sclerosis (MS) disease-modifying therapy (DMT), as defined by persons with MS and panelists.

Figure 2 Provider decision algorithm: Considerations in retirement discussion and recommendation Provider decision algorithm: Considerations in retirement.

Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.

Figure 1 8-Iso-PGF2α levels in CSF of patients with MS and controlsCSF 8-iso-prostaglandin F2α (8-iso-PGF2α) levels were estimated using an ELISA. (A)

Figure 3 Stepwise strategy of bioinformatic analysis of sequencing results We obtained 7,292,715 and 303,698 DNA sequence reads from the affected brain.

Figure 2 Forest plots for subgroup analyses

Figure 5 Neurite structure is not disrupted by the lack of neurofilament light (NEFL)‏ Neurite structure is not disrupted by the lack of neurofilament.

Figure 1 Characteristics of the German National MS Cohort

Figure 1 Time points of blood sampling

The road map from clinical data generation to natural language processing data enrichment, to machine learning data analysis, to clinical decision making. EMR, electronic.

Enrollment and Outcomes

Figure 2 JCV index JCV index (A) Fifty samples of natalizumab-treated patients with multiple sclerosis were assessed twice for their anti-JCV antibody.

Figure 1 Evolution of blood cell counts during 18-month treatment and follow-up (A) Mean white blood cell count, (B) mean lymphocyte count, (C) mean eosinophil.

Figure 5 Schematic overview of a clinical decision-support

Schematic representation of hepatitis E virus (HEV) genotype 3 in developed countries. Schematic representation of hepatitis E virus (HEV) genotype 3 in.

Figure 3. Comparison of median manual muscle test scores in the upper and lower limbs Comparison of median manual muscle test scores in the upper and lower.

Figure 1 Within-groups sum of squares vs number of clusters Within-groups sum of squares vs number of clusters to determine the number needed for k-means.

Figure 4 Voltage-clamp recordings of KCNJ18 carrying the patient's SNVs expressed in Xenopus laevis oocytes under control conditions and after application.

Figure 1 JCV serostatus JCV serostatus (A) Serostatus of 1,921 natalizumab-treated patients with multiple sclerosis, with JCV− patients shown in black.

Figure 5 Pairwise correlations between selected patient-reported outcomes and performance tests in patients with MS (A) The number of pairwise correlations.

Figure 3 Longitudinal performance of 2 MS–cohabitant participant pairs on Ishihara color testing Both response speed and response accuracy are provided.

Figure 2 Individual EDSS scores

Figure 4. Electron microscopic findings in AP-5 patient cells

Figure 1 Annual trend in specimen type submitted as first sample for aquaporin-4 immunoglobulin G testing (serum only vs CSF only vs both) from 101,065.

Figure 2 Reduced frequency of central memory CD4 T cells in patients with PML Reduced frequency of central memory CD4 T cells (CD4Tcm) (p < ), naive.

Figure 5 Autopsy Mycoplasma DNA analysis

Figure 2 Clinical and autoantibody status of 2 CNTN1 or NF155+ patients not receiving rituximab Despite corticosteroids and methotrexate treatment, patient.

Figure 1 Patterns of study retention The proportion of individuals actively participating in the study is displayed over the course of the study. Patterns.

Figure 4 Gray and white matter structural connectivity analyses in patients with PPA according to KIAA0319 genotype Pattern of gray matter (A) and white.

Figure 1 Percentage distribution according to severity of baseline behavioral changes in behavioral variant frontotemporal dementia (bvFTD) and semantic.

Figure Molecular structure Molecular structure of delta-9-tetrahydrocannabiol (THC) (left), which has psychoactive properties, compared to molecular structure.

Figure 1 Considerations for concussed athletes leading to medical care or return to sport (RTS)‏ Considerations for concussed athletes leading to medical.

Figure 2. Patient stratification by the reported duration of symptoms and disease severity at the time of assessment Patient stratification by the reported.

Figure 2 Quality stages by disorder The x-axis lists each of the quality improvement and practice-based research projects in order of implementation at.

The road map from clinical data generation to natural language processing data enrichment, to machine learning data analysis, to clinical decision making. EMR, electronic.

Figure Spinal cord imaging (A, B) Sagittal and axial T2-weighted cervical spine MRI demonstrating hyperintensities in the central gray matter of patient.

Figure 2 Neuroimaging characteristics of TARDBP carriers

Figure Meta-analysis of 9 studies of patients with attention-deficit/hyperactivity disorder (ADHD) vs controls Meta-analysis of 9 studies of patients with.

Figure 2 Kaplan-Meier survival curves for the fingolimod cohort In each graph, bottom tertile: solid line; middle tertile: long dashed line; top tertile:

Figure 2 Seizure outcomes

Figure 1 Classical pathway and lectin pathway activity in patients with multifocal motor neuropathy and controls Classical pathway (CP) activity (A) and.

Module 6: Case Report Form (Chart Abstraction)

7th East African Health and Scientific Conference

Figure Interactive world map

Figure 2 MRIs (cases 2 and 3)‏

This figure illustrates the importance of heart failure consideration in primary endpoint trials with hypoglycemic agents. This figure illustrates the.

Headache frequency after medication withdrawal in medication-overuse headache. Headache frequency after medication withdrawal in medication-overuse headache.

Figure 2 Model representations of performance on functional and behavioral measures over time for behavioral variant frontotemporal dementia (bvFTD) and.

General Medical Council’s (GMC) National Training Survey results for average clinic attendance per week at 33 sites across the UK in General Medical.

Figure 1 Numbers/seropositivity rates of IVIg-naive and IVIg-exposed STRATIFY-2 enrollees* = % of enrollment samples, ** = date of IVIg and/or concentration.

Figure 2. Percentage of CD16− monocytes in the blood is reduced during disease progression Percentage of CD16− monocytes in the blood is reduced during.

Figure (A and B) Effect of canakinumab in muscle strength measured in each patient as mean bilateral GF (A) and TMS (B) during the mean study period of.

Figure 4 Longitudinal analysis of peripheral immune cell composition Frequency of naive, central memory (Tcm), and effector memory (Tem) CD4 T cells over.

Presentation transcript:

Figure 1 Our quality journey Quality improvement and practice-based research in neurology using the electronic medical record (EMR) consists of a stepwise progression from the development and implementation of structured clinical documentation support (SCD... Our quality journey Quality improvement and practice-based research in neurology using the electronic medical record (EMR) consists of a stepwise progression from the development and implementation of structured clinical documentation support (SCDS) toolkits (including note writing and electronic data capture); to enrollment reports; to data quality reports (and data cleaning); to descriptive reports of cohort characteristics; to quality improvement projects (including the creation of benchmark data and quality improvement dashboards); to the use of clinical decision support tools (to hardwire patient safety and improved outcomes); to the use of subgroup-based adaptive assignments (in support of pragmatic clinical trials and personalized medicine); to other research (e.g., biobanking of DNA and the association of genotypes with longitudinal outcomes). The EMR provides a framework for measuring and impacting the 3 dimensions of quality improvement: structure, process, and outcomes. Demetrius M. Maraganore et al. Neurol Clin Pract 2015;5:419-429 © 2015 American Academy of Neurology